Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

Unlike many other pediatric cancers, osteosarcoma has many abnormalities found on genetic analysis of the tumor itself. Dr. Sweet Cordero and colleagues hypothesize that some of these abnormalities could be used to predict what treatment might work best for each specific osteosarcoma patient. For example, many osteosarcomas have genetic alterations that block their ability to "repair" their DNA using specific pathways. One of these defective pathways is called the "homologous repair" pathway and another is called the "alternative lengthening of chromosomes" pathway. The inability of osteosarcoma tumors to repair their DNA using these pathways may make them susceptible to specific drugs. However, it is very likely that these drugs will need to be used in combination and not alone. A key need to advance osteosarcoma patient care is to define and use appropriate model systems to test drugs before using them in patients. This project is combining both preclinical studies in PDX models and a clinical trial to develop new ways to treat osteosarcoma patients with the goal being to improve survival for patients with relapsed and metastatic disease.

This multi-year grant is named for and funded by the Battle Osteosarcoma Hero Fund inspired by and established in honor of Charlotte, Dylan, Tyler and all OsteoWarriors. Led by parents, its mission is to raise funds for promising osteosarcoma precision oncology research to improve treatment options and outcomes for kids battling osteosarcoma.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a nurse navigator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Adolescent and Young Adult (AYA) patients with cancer form a unique group, different than both little children and older adults with cancer. Historically the AYA cancer population has delayed access to care, delay in diagnosis, inconsistent treatment and follow-up, and decreased participation in clinical trials, often leading to inferior survival and quality of life compared to either younger children or older adults. Stony Brook Cancer Center recently started a formal AYA cancer program, with the goal of providing enhanced care and research for AYA patients. This grant supports a nurse navigator for the AYA program, to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports an Adolescent and Young Adult (AYA) Clinical Research Nurse to ensure that more AYAs can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Fortunately, the majority of children with cancer can be cured of their disease. For those children that are not cured, new therapies and new approaches are needed. Additionally, for those children who are cured, we need to work on decreasing the risk of long-term side effects by understanding how chemotherapy medications are metabolized in each individual patient and developing more targeted therapies to decrease off-target side effects. Children's Hospital & Research Center Oakland is currently in process of developing a tumor/tissue bank in order to have patient samples available for collaborative researchers to help tackle some of these questions in order to improve the outcomes and side effects for children with cancer. Some of the research collaborators who are currently utilizing samples from the tumor bank are looking at new methods to harness the immune system to help with killing cancer cells which can minimize some of the side effects from chemotherapy. Additionally they are using samples from the tumor bank to look at the genetics of each person's particular cancer to help identify potential therapeutic targets. Researchers can also utilize this genetic information to answer other genetic questions such as why certain patients metabolism certain chemotherapy medications so differently than other patients and ultimately why certain drugs appear more effective in certain patients than others. This grant supports a Clinical Research Associate to support the tumor/tissue bank.

Adolescent and young adults with cancer (AYAs) represent a unique group of patients that do not do as well on treatment when compared to younger children and older adults. There are many reasons why AYAs do not do as well, which include the specific types of cancers that affect this age group, poor participation in clinical trials, psychosocial challenges of being a teenager with a cancer diagnosis, and the location of cancer treatment. This grant supports the development of an AYA program that will help meet the specific needs of this patient population, with a focus on increased access to clinical trials, to improve overall outcomes.

This grant supports a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.